HCP Early Psychosis 1.1 Data Release: Reference Manual

19 August 2021
Table of Contents

1.0 Background and Rationale ................................................................. 3
2.0 Dataset Overview and Changes since Last Release ......................... 4
3.0 Clinical Research Sites ...................................................................... 4
4.0 Study Population (Inclusion/Exclusion Criteria) .............................. 5
5.0 Study Procedures .............................................................................. 7
   5.1 Clinical Assessments and Procedures ........................................... 7
   5.2 MRI Procedures ........................................................................... 9
6.0 HCP-EP Release 1.1 Data ................................................................. 9
   6.1 Requesting Access to NDA ............................................................. 9
   6.2 Selecting Data for Download ......................................................... 10
7.0 References ....................................................................................... 15
1.0 Background and Rationale

The primary goal of the “Human Connectome Project for Early Psychosis” is to acquire high quality data consistent with the data acquired as part of the original Young Adult HCP, focused on a cohort of young adults with early phase psychosis (both affective and non-affective psychosis), within the first 5 years of the onset of psychotic symptoms.

The significance of this protocol is fourfold:
1) We address an important problem, early phase affective and non-affective psychoses, within 5 years of the initial onset of psychotic symptoms. This is an important cohort to study given that this is a time period early in the course of illness when there are fewer confounds such as prolonged medication exposure and the effects of chronicity, and it is also a time period when treatment intervention strategies may be most effective. Moreover, there is strong evidence that there are both common and distinct brain processes underlying these cohorts (e.g., Berrettini 2003; Murray et al., 2004; Baker et al., 2014). Accordingly, we have acquired a large volume of high quality data on these cohorts using the HCP Lifespan acquisition protocols for imaging, behavior, and cognition.

2) High quality data is maintained by performing data analysis and quality control procedures consistent with the original HCP. Here, we have used the HCP Lifespan imaging sequences at Brigham and Women’s Hospital (BWH), McLean Hospital, and at Indiana University (IU).

3) We are also providing novel and modified tools that can be used in any HCP study, which can be downloaded from a public github repository for general use by the scientific community (https://github.com/pnlbwh). These tools include a new signal drop detection algorithm to facilitate data quality check, a multi-tensor tractography algorithm (Malcolm et al., 2010) essential to extract accurate connectomes from high angular resolution HCP data, a harmonization algorithm for diffusion magnetic resonance imaging (dMRI) data acquired across sites (Mirzaalian et al., 2015), and an algorithm that estimates free water from dMRI (Pasternak et al., 2009).

4) Lastly, as part of a separate project (R01MH117012), participants are evaluated at two follow-up timepoints in order to map brain, cognitive and clinical trajectories during this early course of illness compared to controls. **Note HCP-EP Release 1.0 and 1.1 have included only baseline measures.** Longitudinal follow-up data are included under a separate NDA collection (Collection Title: Neuroprogression across the Psychosis Spectrum in the Early Course of Illness; Collection ID: 3179).
2.0 Dataset Overview and Changes since Last Release

The August 2021 HCP-EP Release 1.1 on NDA contains behavioral data for 251 subjects (69 subjects added since the 1.0 release). Cohort assignment is as follows: 57 affective and 126 non-affective psychotic patients and 68 matched healthy controls. Updated MRI data is provided for 183 (unprocessed, all modalities) and 169 (minimally processed structural MRI) of these subjects (the same group of subjects as in HCP-EP Release 1.0). Updates were made to the processed structural MRI data such that CIFTI brain maps (e.g., *.dlabel.nii and *.dscale.nii files) that were inadvertently excluded were reinstated.

See Table 1 for enrollment by site for subjects in this data release.

In addition to the added subjects for the Clinical Assessments and Procedures, corrections were made to some individual subject’s values for variables in the following NDA structures:

- scid_v01 (Structure Clinical Interview (SCID-5-RV))
- ndar_subject01 (Research Subject and Pedigree)
- cains01 (Clinical Assessment Interview for Negative Symptoms (CAINS))
- psychosocial01 (Diagnosis Form)

The specific changes made can be found in Appendix 3: HCP-EP Release 1.1 Change Log.

3.0 Clinical Research Sites

Below we describe the 4 clinical recruitment sites:

**Indiana University (IU) Psychotic Disorders Program, Prevention and Recovery for Early Psychosis (PARC).** Eskenazi Midtown Community Mental Health PARC is a specialty program for early psychosis located in Indianapolis, Indiana and is an affiliate of Indiana University. PARC is the only comprehensive early psychosis specialty program in central Indiana and serves a population of over 1 million. Founded in 2009 by the study Multiple-PI Dr. Breier, and currently directed by him, PARC is a comprehensive treatment clinic, training program, and research center. PARC’s recruitment program is funded by federal and state grants. PARC averages 7 new intakes per month (84 annually).

**Beth Israel Deaconess Medical Center – Massachusetts Mental Health Center (BIDMC-MMHC), Prevention of and Recovery from Early Psychosis (PREP) Program.** The early psychosis program at BIDMC-MMHC, directed by Dr. Keshavan (BIDMC Site-PI), began in the 1990’s as a clinical psychopharmacology program and includes the PREP clinical outpatient program, the CEDAR (Center for Early Detection, Assessment and Response to Risk) High Risk (“prodromal”) outpatient program, and an inpatient psychiatry unit. Referrals to the CEDAR clinical and research program are approximately 75/year and many of these putatively prodromal individuals have
had a first episode of psychosis and are referred into first episode programs. PREP receives approximately 100 referrals annually, and usually maintains a census of 50 patients.

**McLean Hospital, McLean On Track.** McLean On Track is a specialty first episode psychosis program within the Psychotic Disorders Division at McLean Hospital, where Dr. Öngür (McLean Hospital Site-PI) is Chief. McLean on Track usually maintains a census of about 100 patients. Patients meeting study criteria will also be referred by treating physicians from the McLean Psychotic Disorders inpatient units where Dr. Ongur is also Chief.

**Massachusetts General Hospital (MGH), First Episode and Early Psychosis Program (FEPP).** FEPP is a specialty research and clinical program within the Schizophrenia Clinical and Research Program (SCRP), Department of Psychiatry of MGH. It is located in the outpatient department of MGH. Patients meeting study criteria will also be referred by treating physicians on the MGH Wang 8 inpatient unit. The majority of FEPP patients participate in research. The FEPP program usually maintains a census of about 80 patients. Dr. Holt is the Site-PI.

<table>
<thead>
<tr>
<th>Sites</th>
<th>Patient</th>
<th>Control</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>IU</td>
<td>90</td>
<td>26</td>
<td>116</td>
</tr>
<tr>
<td>BIDMC</td>
<td>25</td>
<td>11</td>
<td>36</td>
</tr>
<tr>
<td>MGH</td>
<td>10</td>
<td>13</td>
<td>23</td>
</tr>
<tr>
<td>McLean</td>
<td>58</td>
<td>18</td>
<td>76</td>
</tr>
<tr>
<td>TOTAL</td>
<td>183</td>
<td>68</td>
<td>251</td>
</tr>
</tbody>
</table>

| 4.0 Study Population (Inclusion/Exclusion Criteria) |
---|

Medically stable male and female subjects with a confirmed psychiatric diagnosis and healthy control subjects were enrolled in the study.

**Inclusion Criteria (all three subject cohorts):**
- 16 to 35 years of age at study entry
- Male or female
- Ability to provide informed consent or have a legal authorized representative or guardian
- Outpatient
- Fluent in English.
- Female subjects of childbearing age report that they are not pregnant and must test negative on a urine pregnancy test at the MRI visit.*
- Willing to share de-identified data with the Connectome database
- Meets additional inclusion criteria for one of the three subject cohorts described below

**Cohort 1: Non-Affective Inclusion Criteria:**
• DSM V** diagnosis of schizophrenia, schizophreniform, schizoaffective, psychosis NOS, delusional disorder, or brief psychotic disorder with onset within the past five years prior to study entry

**Cohort 2: Affective Inclusion Criteria:**
• DSM V** diagnosis of major depression with psychosis (single and recurrent episodes) or bipolar disorder with psychosis (including most recent episode depressed and manic types) with onset within five years prior to study entry

**Cohort 3: Healthy Control Inclusion Criteria*****:
• Does not meet the criteria for major depressive disorder (recurrent) or schizophrenia and other psychotic disorders
• Does not meet criteria for current anxiety disorder
• Anxiety disorders are allowable if the total duration of the illness was less than 12 months; has been in remission for at least 12 months; and did not require the use of medication to treat anxiety
• Does not have a first-degree family member diagnosed with a schizophrenia spectrum disorder
• Free of psychiatric medications at the time of study entry
• No history of psychiatric hospitalization

**Exclusion Criteria (all three subject cohorts):**
• Substance-induced psychosis or psychotic disorder due to a medical
• Known IQ less than 70 based on medical history**
• Subjects with known medical history of Human Immunodeficiency Virus positive (HIV+) status
• Subjects with an active medical condition that affects brain or cognitive functioning (e.g., seizure disorder, epilepsy, head trauma, stroke, traumatic brain injury, significant loss of consciousness, or other neurological disorder) in the site principal investigator’s opinion
• Subjects with implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, ventriculoperitoneal shunt, or other contraindication to undergoing an MRI scan
• Current severe substance use disorder in past 90 days (excluding caffeine and nicotine)
• ECT treatment in past 12 months
• Subjects considered a high risk for suicidal acts – active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening
• Subjects who demonstrate overtly aggressive behavior or who are deemed to pose a substantial risk of danger in the Investigator’s opinion

* Female subjects, including minors, who tested positive for pregnancy were informed at the time of testing. Site PI’s were informed and addressed this issue with subjects on an individualized case by case basis.

** Inclusion/Exclusion criteria related to diagnosis and IQ are based on history and the patient phone screen and were confirmed during the screening assessments by the SCID-5-RV and the WASI-II, respectively.

*** Healthy control inclusion criteria are based on reported history and the healthy control phone screen but were confirmed during the SCID-5_RV screening assessment.
5.0 Study Procedures

The following assessments and procedures were completed by study personnel trained to administer the instruments and were based on interviews with the subject or questionnaires completed by the subject.

5.1 Clinical Assessments and Procedures

Whenever possible, all clinical assessments and procedures were administered to all subjects regardless of subject cohort unless otherwise specified. Clinical Assessments and procedures, including NIH Toolbox measures and additional cognitive assessments, for Boston area subjects occurred at BIDMC-MMHC, McLean Hospital, and MGH. MRI scans for Boston area subjects occurred at BWH, BIDMC, or McLean Hospital. Clinical and cognitive assessments and MR scans for IU subjects occurred at the IU School of Medicine.

**Timing of Measures:** The NIH Toolbox measures were completed in approximately 1.5 to 2 hours; the non-toolbox HCP Lifespan measures, and the additional HCP early psychosis measures took, on average, 2 to 2.5 hours to complete. All subjects were given breaks as needed. Testing occurred over two or more days, but within days of the imaging.

**Screening Assessments:** In addition to the measures listed below, all subjects completed a screening interview where demographics, family psychiatric history, screening for history of traumatic brain injury and contraindication to MRI testing were assessed.

**Medical History:** The subject’s lifetime medical history were assessed during the screening period. Medical history included previous and current diseases and lifetime and current substance use. All concomitant medications were recorded in the source documentation. In order to address the potential effects of antipsychotic drugs on structural and functional indices lifetime antipsychotic medication dosage as CPZ equivalents using the Gardner approach (Gardner et al., 2010) were calculated for non-affective and affective subject cohorts.

**Structured Clinical Interview (SCID-5-RV)** (First et al., 2015), in conjunction with medical records and/or clinical interviews, was administered to all subjects, both patients and healthy controls, to rule out patient subjects who were not psychotic or who had a psychosis that was related to substance abuse or to an organic disease. The SCID-5-RV was also used to confirm that healthy control subjects did not meet criteria for bipolar and related disorders, major depressive disorder (recurrent) or schizophrenia and other psychotic disorders.

**NIH Toolbox Measures**
The following battery was included in the NIH Toolbox Measures (NIH Toolbox, 2013; Toolbox-CB, 2013; McDonald, 2014; Hodes et al., 2013).
HUMAN Connectome Project for Early Psychosis

- **Cognition** (Picture Sequence, Dimensional Change, Flanker, Picture Vocabulary, Pattern Completion, List Scoring, and Oral Reading)
- **Emotion** (Self-report emotion)
- **Sensation** (Words in Noise, Odor Identification, and Dynamic Visual Acuity)
- **Motor** (9-Hole Pegboard, and Grip Strength)

**Additional Cognitive Assessments**
- **HCP Lifespan Measures** (Gur et al., 2001; Gur et al., 2009).
  - Delay Discounting
  - Penn Emotion Recognition
- **WASI-II** (Wechsler, 2011)
- **Seidman Auditory Continuous Performance Test** (CPT; Seidman et al., 1998; Seidman et al., 2012)

**Positive and Negative Syndrome Scale (PANSS)** (Kay et al., 1987) is an assessment instrument for general psychopathology and positive symptoms. The PANSS contains 30 items that assess symptoms of psychotic disorders including positive, negative and general psychopathology. The PANSS was chosen because of its widespread use in clinical studies of psychosis, and its demonstrated reliability in assessing psychopathology across diverse patient populations.

**Hollingshead Two-Factor Parental Socioeconomic Status Scale** (Hollingshead, 1957) Parental SES is a standard matching variable in psychosis imaging studies because of the downward socio-economic drift associated with these illnesses.

**Clinical Assessment Interview for Negative Symptoms (CAINS)** (Kring et al., 2013; Forbes et al., 2010; Horan et al., 2011). This is a 13-item negative symptom scale developed and endorsed by the NIMH’s Consensus Development Conference on Negative Symptoms. We selected it because of its high reliability and the validation of two key factors - affect and avolition/motivation – that may be used for domain specific analyses.

**Young Mania Rating Scale (YMRS)** (Young et al., 1978). This is an 11-item clinician administered assessment scale for mania and one of the most commonly used scales to assess severity of mania.

**Montgomery-Asberg Depression Rating Scale** (MADRS) (Montgomery and Asberg, 1979). This is a 10-item clinician administered depression rating scale that has established reliability in both schizophrenia and mood populations.

**MIRECC Global Assessment of Functioning (GAF)** (Niv et al., 2007) provides global assessments of symptoms, work/school and social functioning. The GAF is commonly used in early stage psychosis studies.
5.2 MRI Procedures

**MRI Data Acquisition Protocol** (duration = approximately 70 minutes)

This project used three Siemens MAGNETOM Prisma 3T scanners at BWH, McLean, and IU. BWH and IU used a 32-channel head coil. The McLean used a 64-channel head & neck coil, with the neck channels turned off. All protocols were based on the 2016 CCF template protocol. Detailed imaging protocols for the three imaging sites are in Appendix 1.

In short, the protocol scan sequences were:

- **T1w (MPRAGE)** and T2w (SPACE) structural scans of 0.8mm isotropic resolution.
- Resting state fMRI (rfMRI) of 2mm isotropic resolution, multiband (MB) acceleration factor of 8, TR 720ms, acquired twice: once with AP and once with PA phase encoding.
- Diffusion MRI (dMRI) 1.5mm isotropic, MB acceleration factor of 4, 92 directions in each shell (b=1500 and 3000) acquired twice: once with AP and once with PA phase encoding. The first two acquisitions include 3 additional directions at b=200 and 6 directions at b=500 to improve modeling of fast diffusion processes such as free water.
- In addition, field maps were acquired to correct for intensity and geometric distortions.

**Positioning and motion:** Subjects were instructed to remain still during scanning and deformable foam cushioning was used to stabilize the head. Real time image reconstruction and processing were used for quality assurance at the time of scanning. If there was any detectable problem, the scan was repeated. **Noise:** Noise-attenuating headphones and ear stopples were used and provided excellent noise reduction while still permitting adequate auditory perception.

6.0 HCP-EP Release 1.1 Data

6.1 Requesting Access to NDA

Connectomes Related to Human Disease (CRHD) projects like HCP-EP and Lifespan HCP (Aging & Development) data managed and processed by the Connectome Coordination Facility (CCF) are being released through the NIMH Data Archive (NDA), a data repository funded by the National Institutes of Health (NIH).

HCP-Aging, HCP-Development, and CRHD imaging and behavioral data are currently only being shared through NDA.
Gaining approval for a new request for NDA access is a multistep process that may take some time, possibly a few weeks, to gather the necessary information and signatures, especially if you are at an institution that must establish the eligibility requirements. Full instructions for obtaining access on NDA, including screenshots of the process, are available in the Lifespan HCP 2.0 Release Data Access & Download Instructions.

Once approved, access is valid for one full year. To maintain access, a renewal request should be submitted through the same process.

### 6.2 Selecting Data for Download

To obtain data from the HCP-EP Release 1.1, go to the Connectomes Related to Human Disease Featured Datasets query page. You can also get to this page by selecting “Get Data” from the NDA home page (pictured above), then selecting “Human Connectome Projects > Connectomes Related to Human Disease” at the top left of the query page.

On the Connectomes Related to Human Disease Featured Datasets query page, the user has two options for accessing the HCP-Early Psychosis data.

**OPTION ONE**

**OPTION ONE** accesses 2 premade, HCP-EP Release 1.1 shared data packages that we recommend as a starting point for download for many users. The HCPEP11AllData package contains all released data, and HCPEP11UnprocBehData contains unprocessed imaging data. Both packages contain the full released clinical and behavioral data.

Click on the “Access Shared Data Packages” button.

On the Data Packages page, in the Actions column in the row of the package you are interested in, select “Add to My Data Packages” (pink arrow). It will take some time (seconds to several
minutes depending on size) to add
the package to your account and
there should be a notification at
the top of the page when it is
complete.

In the meantime, you can proceed
with downloading and setting up
the Java Download Manager or
nda-tools for downloading on the
command line. Full instructions for
using these download options are
available in the Lifespan HCP 2.0
Release Data Access & Download Instructions.

Note: We do not recommend using NDA’s “Download Manager Beta” (button on the Data
Packages page) at this time due to performance issues and long download times.

OPTION TWO

OPTION TWO allows the user to
select modality- and processing
output-specific “HCP-style
package” filters to access part of
the released data by clicking the
nested dropdown options under
HCP-Early Psychosis Release 1.1
Available Datasets.

On the Connectomes Related to
Human Disease Featured Datasets
query page, under OPTION TWO,
click the triangles next to the data
types to reveal all the subset
options (pink arrow). Click the black
“i” information buttons (blue
arrow) to see a description of the subset package.

Select the checkboxes of the subsets of the data you are interested in and click the “Add to
Workspace” button at the bottom of the page (cyan arrow).

Note: The OPTION TWO subset package filters filter for data from all released subjects and are
additive (if you make more than one selection), so total data sizes may become large. If you are
interested in downloading one or a few subjects, see Filtering by Subjects in the Lifespan HCP
2.0 Release Data Access & Download Instructions.
Click on the Filter funnel icon at the top right (green arrow) showing the number of filters you added. This will show your Workspace, click “Submit to Filter Cart” at the bottom. It can take several minutes to update the Filter Cart at the top right.

When finished, click on “Create Data Package/Add to Study” (pink arrow) at the bottom of the Filter Cart box at the top right.

On the Data Packaging page, you’ll see the data you selected listed in NDA Data Structure categories (mostly useful for Behavioral data, click on the “i” buttons to see a tabular preview of the data).

Click the “Create Data Package” button to create your custom package.

Enter a Package Name, be sure to click the “Include associated data files” checkbox (MRI data are considered associated data files), and “Exclude null columns” (pink arrows), so the behavioral data will not have extraneous columns for unused variables.

Click “Create Data Package”. The process of creating the package will take several minutes and can be tracked from your Packages Dashboard, with “My Packages” selected at the top left. You may need to refresh the page to see the status change.

While you are waiting, follow the instructions in the Lifespan HCP 2.0 Release Data Access & Download Instructions to download the Java Download Manager or command line download tools. You can also track package creation within the Java Download Manager GUI by clicking the Refresh Queue button until your package is listed as ready to download.

6.3 Files and Directory Structure

The user may choose to download the MRI unprocessed data, preprocessed structural data and the behavioral data by selecting prepackaged data or choose to create their own custom package as described above.

Note: The age of each subject recorded in the imaging, general demographics, and behavioral instruments may be inconsistent, because the time interval between subject consenting, MR scanning, and behavioral assessments was sometimes large (in the order of a few months).
The data package will download to the Save To: location on your file system with the top directory name matching the package name (<YourPkgName>, or, e.g., HCPEP).

If your package contains Minimally Preprocessed Image Data, and Unprocessed Image Data, the high-level <YourPkgName> directory will contain:

<YourPkgName>/
   fmriresults01/ Preprocessed data (currently only Structural MRI)
   fmriresults01.txt Info on preprocessing pipelines run (per subject)
   imagingcollection01/ Unprocessed data
   imagingcollection01.txt Listing of per subject data (by modality) in collection
   md5_values.txt md5 checksums for download verification
   package_info.txt Info on NDA filters used to create package
   README.pdf automatic README from NDA

We are using the NDA data structures fmriresults01 and imagingcollection01 (full directory structure described in Appendix 2) to organize the preprocessed and unprocessed, respectively, per subject data into the same directory structure as that of previously released HCP Young Adult data, so that it is compatible with the expected inputs and outputs of processing through the HCP Pipelines.

The fmriresults01/ directory contains the preprocessed data, currently structural preprocessing outputs only, for the subjects available.

The imagingcollection01/ directory contains unprocessed data of all modalities

Under these two directories, are high level <SubjectID_01_MR>, directories and a manifests directory. Manifests are JSON files (*.json) that organize related data (e.g. unprocessed REST1 data) into a structured set of files to be downloaded according to the directory structure specified. In this case, we have used the manifests to organize the data into per subject, unprocessed and processed “packages” as we did for the HCP Young Adult Study in the directory structure output by and required for input to the HCP pipelines.

6.4 Behavioral Data Structures

Behavioral and clinical measures listed in section 5.1 were mapped to the NDA behavioral data structures listed below. If you include Behavioral data in your download package, tab-delimited text files for all behavioral structures you choose to include will be included in the <YourPkgName>/ directory (e.g. er4001.txt).

Notes:
- The ndar_subject01 structure has 1 duplicate subject, NDARGK424RPR src_subject (project ID) 4098. That is why NDA counts 252 subjects, when there are only 251 subjects. The other NDA structures do not have duplicate information for this subject. This will be corrected in a future release.
• The following NIH Toolbox instruments were inadvertently not included in HCP-EP Release 1.0, but are now available as part of the behavioral dataset for HCP-EP Release 1.1:

  - cogcomp01  Cognition Composite Scores
  - psm01  Picture Sequence Memory Test Age 8+ Form A v2.1
  - pcps01  Pattern Comparison Processing Speed Test Age 7+ v2.1

### Released behavioral data structures

<table>
<thead>
<tr>
<th>NDA Structure</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>er4001</td>
<td>Penn Emotion Recognition Task-40</td>
</tr>
<tr>
<td>ndar_subject01</td>
<td>Research Subject and Pedigree, includes Phenotype</td>
</tr>
<tr>
<td>acpt01</td>
<td>Auditory CPT</td>
</tr>
<tr>
<td>madrs01</td>
<td>Montgomery-Asberg Depression Rating Scale</td>
</tr>
<tr>
<td>deldisk01</td>
<td>Delay Discounting Task</td>
</tr>
<tr>
<td>tbi01</td>
<td>Traumatic Brain Injury</td>
</tr>
<tr>
<td>reins01</td>
<td>Clinical Assessment Interview for Negative Symptoms</td>
</tr>
<tr>
<td>pred01</td>
<td>NIH Toolbox Sadness CAT Age 18+ v2.0</td>
</tr>
<tr>
<td>cgi01</td>
<td>MIRECC GAF Score Sheet</td>
</tr>
<tr>
<td>socdem01</td>
<td>Demographics Form</td>
</tr>
<tr>
<td>psychosocial01</td>
<td>Diagnosis Form</td>
</tr>
<tr>
<td>scid_v01</td>
<td>SCID-5-RV Score Sheet</td>
</tr>
<tr>
<td>ses01</td>
<td>Parental SES Hollingshead-Rendlich</td>
</tr>
<tr>
<td>mhx01</td>
<td>Lifetime Antipsychotic Drug Exposure</td>
</tr>
<tr>
<td>presio01</td>
<td>Nicotine Tracking</td>
</tr>
<tr>
<td>panss01</td>
<td>PANSS QuickScore</td>
</tr>
<tr>
<td>olfact01</td>
<td>Olfactory Questionnaire</td>
</tr>
<tr>
<td>wasi201</td>
<td>WASI II</td>
</tr>
<tr>
<td>fmhx01</td>
<td>FIGS Data Screen</td>
</tr>
<tr>
<td>cogcomp01</td>
<td>Cognition Composite Scores</td>
</tr>
<tr>
<td>dccs01</td>
<td>NIH Toolbox Dimensional Change Card Sort Test v2.1</td>
</tr>
<tr>
<td>flanker01</td>
<td>NIH Toolbox Flanker Inhibitory Control and Attention Test v2.1</td>
</tr>
<tr>
<td>lswmt01</td>
<td>NIH Toolbox List Sorting Working Memory Test v2.1</td>
</tr>
<tr>
<td>orrt01</td>
<td>NIH Toolbox Oral Reading Recognition Test Age 3+ v2.1</td>
</tr>
<tr>
<td>pcps01</td>
<td>Pattern Comparison Processing Speed Test Ages 3-6 v2.1</td>
</tr>
<tr>
<td>prang01</td>
<td>PROMIS Anger</td>
</tr>
<tr>
<td>promisgl01</td>
<td>Social Satisfaction Summary</td>
</tr>
<tr>
<td>prsi01</td>
<td>NIH Toolbox Loneliness FF v2.0</td>
</tr>
<tr>
<td>psm01</td>
<td>NIH Toolbox Picture Sequence Memory Test v2.1</td>
</tr>
<tr>
<td>pss01</td>
<td>NIH Toolbox Perceived Stress Scale</td>
</tr>
<tr>
<td>self_effic01</td>
<td>NIH Toolbox Self-Efficacy CAT v2.0</td>
</tr>
<tr>
<td>tlbx_emsup01</td>
<td>NIH Toolbox Emotion Domain – Emotional Support Survey</td>
</tr>
</tbody>
</table>
tlbx_fearanx01  NIH Toolbox Emotion Domain - Fear Surveys
tlbx_friend01  NIH Toolbox Emotion Domain - Friendship Survey
tlbx_motor01  NIH Toolbox Motor Domain
tlbx_perhost01 NIH Toolbox Emotion Domain - Perceived Hostility Surveys
tlbx_rej01    NIH Toolbox Emotion Domain - Peer Rejection and Perceived Rejection Surveys
tlbx_sadness01 NIH Toolbox Emotion Domain - Sadness Surveys
tlbx_socwit01 NIH Toolbox Emotion Domain - Social Withdrawal and Positive Peer Interaction Surveys
tlbx_sensation01 NIH Toolbox Sensation Domain
tlbx_wellbeing01 NIH Toolbox Emotion Domain - Psychological Well-Being
tpvt01       NIH Toolbox Picture Vocabulary Test

7.0 References


